4DMedical aims to turbocharge US rollout after pulling in $150m from global funds
After a transformative run of regulatory wins and commercial deals, the company has secured the backing of major investors in the first big equity raise of the year led by Bell Potter.
Surging ASX small cap 4DMedical’s founder and chief executive Andreas Fouras said his company's “infinitely scalable” software will rapidly corner the lucrative US market after closing the ASX’s first major capital raise of the new year.
Bell Potter’s Andrew James held the pen on the $150 million raise, announced Thursday morning, which attracted cornerstone investments from three as yet unnamed long-only institutional investors, and more than a dozen other global funds.
Fouras said the institutional placement was driven by a flood of inbound interest after a transformative five months for the company.
Since landing a $10 million investment from medical imaging giant Pro Medicus at the end of July, 4DMedical has secured regulatory clearance for its flagship lung imaging software CT:VQ in the US and Canada, received a reimbursement approval from the US Centers for Medicare & Medicaid Services, and inked a distribution deal with healthcare powerhouse Philips.
